Pulmatrix submits NDA to FDA to initiate Phase 2 trial of PUR3100

Pulmatrix announced the submission of an investigational new drug application to the United States FDA for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine, under development to treat acute migraine. The PUR3100 formulation uses Pulmatrix’s novel, proprietary dry powder delivery technology, iSPERSE to deliver DHE directly into the lungs using a dry-powder inhaler.